Drug Markets in Cognitive Dysfunction Will Experience Dramatic Transformation as...

Drug Markets in Cognitive Dysfunction Will Experience Dramatic Transformation
as Total Sales Increase From $300 Million in 2006 to $3.7 Billion in 2016
Launches of New Therapies Will Boost Diagnosis and Drug-Treatment Rates,
According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 15 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that the market for cognitive dysfunction-which encompasses
several distinct disorders-will experience a dramatic overall sales increase,
transforming the market from a meager $300 million in 2006 to $3.7 billion in
2016, driven by sales of new drugs from Myriad Genetics, Elan/Wyeth,
Targacept/AstraZeneca and Memory Pharmaceuticals/Roche. Four key cognitive
dysfunctions are considered in the report-mild cognitive impairment, cognitive
impairment associated with schizophrenia, cognitive dysfunction in multiple
sclerosis and cognitive dysfunction in traumatic brain injury.
The new Pharmacor report entitled Cognitive Dysfunction finds that the
launch of new, expensive therapies over the next several years will boost
diagnosis and drug-treatment rates and propel a 12-fold increase in total
sales, predominantly in the markets for mild cognitive impairment and
cognitive impairment associated with schizophrenia. Myriad Genetics' Flurizan
and Elan/Wyeth's bapineuzumab-the first disease-modifying therapies for
Alzheimer's disease-will be prescribed off-label in mild cognitive impairment,
driving an impressive 56% annual sales growth between 2011 and 2016.
Additionally, Targacept/AstraZeneca's ispronicline and Memory
Pharmaceuticals/Roche's MEM-3454-the first drugs approved for cognitive
impairment associated with schizophrenia-will together fuel a robust 43%
growth in sales over this same period.
"Currently, there are no drugs that are unequivocally effective in
cognitive dysfunction, and off-label treatment is sporadic as less than one-
third of diagnosed patients in any disorder were drug-treated in 2006.
However, the impending off-label use of Flurizan and bapineuzumab in mild
cognitive impairment coupled with the approvals of several new therapies for
cognitive impairment associated with schizophrenia will drive significant
market growth," said Jonathan Searles, analyst at Decision Resources.
"Additionally, despite the absence of approved therapies, considerable
opportunity will remain for agents that effectively treat cognitive
dysfunction in multiple sclerosis and traumatic brain injury-these markets
benefit from high pricing potential, high prevalence in the case of traumatic
brain injury, and low competition."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services, and consulting designed to help
clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:

Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com

SOURCE Decision Resources

Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com